Overview

Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Status:
Enrolling by invitation

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the combination of paclitaxel, capecitabine, mitomycin and intensity-modulated radiotherapy is more effective than the standard combination of capecitabine, mitomycin and intensity-modulated radiotherapy (IMRT) in patients with squamous-cell anal cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Blokhin's Russian Cancer Research Center

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Mitomycin
Mitomycins
Paclitaxel